Impact of T cell selection methods in the success of clinical adoptive immunotherapy (Q42265908)

19 October 2017

title

Impact of T cell selection methods in the success of clinical adoptive immunotherapy (English)

1 reference

19 October 2017

1 reference

Natalia Ramírez

1

1 reference

19 October 2017

Lorea Beloki

2

1 reference

19 October 2017

Miriam Ciaúrriz

3

1 reference

19 October 2017

Mercedes Rodríguez-Calvillo

4

1 reference

19 October 2017

David Escors

5

1 reference

19 October 2017

Cristina Mansilla

6

1 reference

19 October 2017

Eva Bandrés

7

1 reference

19 October 2017

Eduardo Olavarría

8

1 reference

19 October 2017

publication date

1 April 2014

1 reference

Cellular and Molecular Life Sciences

19 October 2017

published in

1 reference

19 October 2017

volume

71

1 reference

19 October 2017

issue

7

1 reference

19 October 2017

page(s)

1211-1224

1 reference

Viral disease prevention after hematopoietic cell transplantation

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Adoptive immunotherapy for posttransplantation viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Adoptive immunotherapy post bone-marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Progressive differentiation and selection of the fittest in the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Effector and memory T-cell differentiation: implications for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Lineage relationship and protective immunity of memory CD8 T cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Successful immunotherapy of HCMV disease using virus-specific T cells expanded from an allogeneic stem cell transplant recipient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Transfer of specificity by murine alpha and beta T-cell receptor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Selected murine residues endow human TCR with enhanced tumor recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Adoptive T cell therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Redirecting gene-modified T cells toward various cancer types using tagged antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Improving the efficacy and safety of engineered T cell therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Inducible apoptosis as a safety switch for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

An inducible caspase 9 safety switch for T-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Viral-specific adoptive immunotherapy after allo-SCT: the role of multimer-based selection strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Multimer technologies for detection and adoptive transfer of antigen-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Sequential production of IL-2, IFN-gamma and IL-10 by individual staphylococcal enterotoxin B-activated T helper lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

The interferon gamma secretion assay: a reliable tool to study interferon gamma production at the single cell level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

CARs on track in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Central memory and effector memory T cell subsets: function, generation, and maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Adoptive immunotherapy for cancer: building on success

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Toward improved immunocompetence of adoptively transferred CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Alloreactive and leukemia-reactive T cells are preferentially derived from naive precursors in healthy donors: implications for immunotherapy with memory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

A human memory T cell subset with stem cell-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

IL-7 is essential for homeostatic control of T cell metabolism in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Human regulatory T cells: role in autoimmune disease and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Antigen-independent activation of naive and memory resting T cells by a cytokine combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Do CD8 effector cells need IL-7R expression to become resting memory cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Loss of IL-7R and IL-15R expression is associated with disappearance of memory T cells in respiratory tract following influenza infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Vigorous HIV-1-Specific CD4 + T Cell Responses Associated with Control of Viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Naive CD4(+) lymphocytes convert to anergic or memory-like cells in T cell-deprived recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Cellular immunotherapy for refractory hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Novel interferon-based pre-transplantation conditioning in the treatment of a congenital metabolic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Phenotypic analysis of antigen-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Antigen-Specific Modulation of an Immune Response by In Vivo Administration of Soluble MHC Class I Tetramers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Dynamics of proximal signaling events after TCR/CD8-mediated induction of proliferation or apoptosis in mature CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Adoptive transfer and selective reconstitution of streptamer‐selected cytomegalovirus‐specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Antitumor effects of HSV-TK engineered donor lymphocytes after allogeneic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1463-5

Functional analysis of cytomegalovirus-specific T lymphocytes compared to tetramer assay in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

12 December 2020

CD25+Foxp3+ regulatory T cells facilitate CD4+ T cell clonal anergy induction during the recovery from lymphopenia

1 reference

12 December 2020

Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients

1 reference

12 December 2020

High doses of mother's lymphocyte infusion to treat EBV-positive T-cell lymphoproliferative disorders in childhood

1 reference

12 December 2020

Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma.

1 reference

12 December 2020

Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.

1 reference

12 December 2020

Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial

1 reference

12 December 2020

Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65.

1 reference

12 December 2020

Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression

1 reference

12 December 2020

Donor T cells to treat EBV-associated lymphoma

1 reference

12 December 2020

Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection

1 reference

12 December 2020

Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions

1 reference

12 December 2020

Immunotherapy for Epstein-Barr virus-associated cancers

1 reference

12 December 2020

Specific expression of surface interferon-gamma on interferon-gamma producing T cells from mouse and man

1 reference

12 December 2020

Background to hematopoietic cell transplantation, including post transplant immune recovery

1 reference

12 December 2020

CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients

1 reference

12 December 2020

Immunotherapy through TCR gene transfer

1 reference

12 December 2020

Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones

1 reference

12 December 2020

Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease

1 reference

12 December 2020

Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

1 reference

12 December 2020

Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions

1 reference

12 December 2020

Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer

1 reference

12 December 2020

Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease

1 reference

12 December 2020

Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation

1 reference

12 December 2020

Adoptive immunotherapy with liver allograft–derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice

1 reference

12 December 2020

Depletion of Tregs in vivo: a promising approach to enhance antitumor immunity without autoimmunity

1 reference

12 December 2020

Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-gamma secretion assay

1 reference

12 December 2020

Syngeneic adoptive transfer of anti-human immunodeficiency virus (HIV-1)-primed lymphocytes from a vaccinated HIV-seronegative individual to his HIV-1-infected identical twin.

1 reference

12 December 2020

Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion

1 reference

12 December 2020

Antigen-specific blockade of T cells in vivo using dimeric MHC peptide

1 reference

12 December 2020

A phase 1 study of adoptive transfer of autologous CD8+ T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS

1 reference

12 December 2020

Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects

1 reference

12 December 2020

Therapeutic potential of genetically modified HBV-specific T cells for chronic HBV infection and HBV-related HCC

1 reference

12 December 2020

Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions

1 reference

12 December 2020

Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients

1 reference

12 December 2020

Memory CD4+ T cells do not induce graft-versus-host disease

1 reference

12 December 2020

Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor

1 reference

12 December 2020

10.1007/S00018-013-1463-5

Identifiers

DOI

1 reference

19 October 2017

1 reference